Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

Schizophrenia Clinical Trial

Official title:

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02658357
• Other study ID #: BB-PK-103
• Status: Completed
• Phase: Phase 2
• Start date: October 2015
• Est. completion date: August 2017

Study information

• Verified date: February 2020
• Source: Braeburn Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will be a 6-month, open-label, multiple center study in approximately 50 stable subjects diagnosed with schizophrenia or schizoaffective disorder to evaluate the safety, tolerability, and pharmacokinetics of Risperidone and 9-OH-Risperidone following implantation of two or three, 300 mg Risperidone Implants.

Description:

The study will be a 6-month, open-label, study in approximately 50 stable subjects diagnosed with schizophrenia or schizoaffective disorder to evaluate the safety, tolerability, and pharmacokinetics of Risperidone and 9-OH-Risperidone following implantation of two or three, 300 mg Risperidone Implants.

Subjects who are diagnosed with schizophrenia or schizoaffective disorder according to DSM-V and are stable on a daily 4 mg oral dose of Risperidone for at least 8 weeks will be recruited into the study.

Subjects stable on a 4 mg oral dose of Risperidone will be implanted with two or three, 300 mg, Risperidone Implants. All implants will be placed in the inner aspect of the upper arm. Plasma concentrations of Risperidone and the active moiety will be measured prior to placement of the Risperidone Implants, throughout the implantation period, and after re-converting to oral Risperidone following the removal of the Risperidone Implants.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 66
• Est. completion date: August 2017
• Est. primary completion date: August 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Subject (and/or a subject's authorized legal representative) has provided written informed consent

2. Patient meets the following criteria:

• Outpatient status

• PANSS Total Score = 80 at screening and if PANSS score at baseline is = 20% change from screening, the patients cannot participate in the study.

• A score of = 3 on the following PANSS items:

• Conceptual disorganization

• Suspiciousness

• Hallucinatory behavior

• Unusual thought content

3. Subject is male or female between 18 to 60 years of age

4. Subject has a diagnosis of schizophrenia or schizoaffective disorder according to Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria

Exclusion Criteria:

1. Hospitalized or required acute crisis intervention for symptom exacerbation in the 60 days prior to admission as determined by the Investigator

2. Subject has a history of suicide attempt in the last year, or in the opinion of the investigator is currently at imminent risk of suicide

3. Has a current or recent (within 12 months) DSM-V diagnosis of moderate or severe substance use disorder (except for tobacco use disorder) or has a positive urine drug screen for prohibited substances at screening.

4. Have impaired hepatic (ALT/AST >1.5 times higher than the upper limit of normal) or renal function (eGFR<50 mL/min)

5. Previously defined hypersensitivity to Risperidone

6. History of neuromalignant syndrome (NMS)

7. Electroconvulsive therapy within 6 months of admission

8. Requires current use of agents that are strong inhibitors and inducers of cytochrome P450 2D6

Related Conditions & MeSH terms

• Mood Disorders
• Psychotic Disorders
• Schizo-affective Disorder
• Schizophrenia

Intervention

Drug:
• Risperidone Implant

Locations

Country	Name	City	State
United States	Segal Institute for Clinical Research 1201 North 37th Avenue	Hollywood	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Braeburn Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area Under the Curve (AUC) for Active Moiety, 9-hydroxy-risperidone and Risperidone		6 months
Primary	Cmax for Active Moiety, 9-hydroxy-risperidone and Risperidone		6 months
Secondary	Safety and Efficacy of a Risperidone Implant as Assessed by the Positive and Negative Syndrome Scale (PANSS)		12 months